Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-11
1999-05-04
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514826, 514864, A61K 3144
Patent
active
059004215
ABSTRACT:
Methods utilizing descarboethoxyloratadine ("DCL"), for the treatment of allergic disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. Also included are methods for the treatment of allergic asthma using DCL and either a decongestant or a leukotriene inhibitor, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. The invention also encompasses the administration of DCL in a nasal or oral spray.
REFERENCES:
patent: 4659716 (1987-04-01), Villani et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5595997 (1997-01-01), Aberg et al.
Anderson et al., "Adverse Drug Interactions Clinically Important for the Dermatologist," Arch. Dermatol., 131:468-473 (1995).
Berthon et al., "In Vitro Inhibition, by Loratadine and Descarboxyethoxloratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophilic Leukemia Cells (RBL-2H3)," Biochemical Pharmacology, 47:(5), pp. 789-794 (1994).
Brandes et al., "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H.sub.1 -Antihistamines: Predictive In Vitro Correlates," J. Nat. Can. Inst. Reports, 86:(10), pp. 770-775 (1994).
Kleine-Tebbe et al., "Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H.sub.1 -antagonist, desethoxycarbonyl-loratadine," J. Allergy Clin. Immunol., 93:(2), pp. 494-500 (1994).
Miadonna et al., "Inhibitory Effect of the H.sub.1 Antagonist Loratadine on Histamine Release from Human Basophils," Int. Arch. Allergy Immunol., (105), pp. 12-17 (1994).
Zhong et al., "HPLC-Bestimmung Von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma," Pharmazie , (49) H.10, pp. 736-739 (1994) (English abstract attached).
Lavrijsen et al., "The Interaction of Ketoconazole, Itraconazole and Erythromycin With the In Vitro Metabolism of Antihistamines in Human Liver Microsomes," Abstract 1233, Eur. J. Allergy Clin. Immunol., 48, Suppl. 16, 34 (1993).
Van Peer et al., "Ketoconazole Inhibits Loratadine Metabolism in Man," Abstract 1234, Eur. J. Allergy Clin. Immunol., 48, Suppl. 16, 34 (1993).
Quercia et al., "Focus on loratadine: A new second-generation nonsedating H.sub.1 -receptor antagonist," Hosp. Formul., (28), pp. 137-153 (1993).
Product Insert CR-318/17597400 Jul. 1993 Schering Corporation (1992, 1993).
Brandes et al., "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses," Cancer Research, (52), pp. 3796-3800 (1992).
Knowles, "Astemizole and Terfenadine -- Induced Cardiovascular Effects," Canadian J. Hosp. Pharm, 45:(1) pp. 33, 37 (1992).
Parkinson et al., "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 In Rats and Mice," Biochemical Pharmacology, 43:(10), pp. 2169-2180 (1992).
"Antihististamines," Chapter 16, Side Effects of Drugs Annual, 14, pp. 135-138, Elsevier Science Publishers (1990).
Clissold et al., "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy," Drugs, 37, pp. 42-57 (1989).
"Antihististamines," Chapter 16, Side Effects of Drugs Annual, 12, pp. 142-143, Elsevier Science Publishers (1988).
Simons et al., "Astemizole -- Induced Torsades de Pointes," Lancet, p. 624 (Sep. 10, 1988).
Temple et al., "Loratadine, an Antihistamine, Blocks antigen-and Ionophore -- Induced Leukotriene Release From Human Lung In Vitro," Prostaglandins, 35:(4), pp. 549-554 (1988).
Hilbert et al., "Pharmacokinetics and Dose Proportionality of Loratadine," J. Clin. Pharmacol., (27), pp. 694-698 (1987).
Craft, "Torsade de Pointes After Astemizole Overdose," British Med. J., (292), p. 660 (1986).
Barnett et al., "Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine," Agents and Actions, 14:(5/6), pp. 590-597 (1984).
Wood, "Antimotion Sickness and Antiemetic Drugs," Drugs, (17), 17 pp. 471-479 (1979).
Cohen et al., "Meclizine and Placebo in Treating Vertigo of Vestibular Origion," Arch. Neurol., (27), pp. 129-135 (1972).
Handley Dean A.
Rubin Paul D.
Jordan Kimberly
Sepracor Inc.
LandOfFree
Methods and compositions for treating allergic asthma and dermat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating allergic asthma and dermat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating allergic asthma and dermat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1869670